Navigation Links
Reportlinker Adds KOL insights and unmet needs in Ulcerative Colitis and Crohn's Disease
Date:5/10/2011

NEW YORK, May 10, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0490908/KOL-insights-and-unmet-needs-in-Ulcerative-Colitis-and-Crohns-Disease.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Introductory offer: buy 2 Sociable Pharma reports get a third free. Introductory offer available until the end of May 2011.

Purchase Sociable Pharma's two reports on KOL insights and unmet needs in Ulcerative Colitis and Crohn's Disease and get Sociable Pharma view on future opportunities and scenarios free.

--Below are summaries of each report.

- Ulcerative Colitis: KOL insights on treatment practices and unmet needs

The use of biologics is still in its formative stages in the treatment of ulcerative colitis but adoption has already been significant and is set to expand considerably in the short- and medium-term. Sociable Pharma conducted in-depth primary research in the US and Europe with key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.

HIGHLIGHTS

Identifies the latest treatment trends in Ulcerative Colitis, including the role of biologics in steroid-refractory patients and acute/severe settings

Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines

Analyzes current treatment practices covering five major drug classes: aminosalicylates (5-ASAs), corticosteroids, immunomodulators, anti-TNF therapies, calcineurin inhibitors

Highlights opinion hotspots where treatment approaches differ between physicians and also between the US and Europe, such as the use of once daily oral dosing formulations for 5-ASAs

Assesses the impact of the 2011 SUCCESS trial

Identifies the most significant unmet needs, based on the treatment challenges facing physicians. Examples include adherence to 5-ASA regimens and managing long-term immunosuppression.

- Crohn's disease: KOL insights on treatment practices and unmet needs

Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.

HIGHLIGHTS

Identifies the latest treatment trends in Crohn's disease, including the growing importance of "top-down" treatment strategies for moderate-to-severe Crohn's disease

Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines

Analyzes current treatment practices covering seven major drug classes: aminosalicylates (5-ASAs), corticosteroids, immunomodulators, anti-TNF therapies, antibiotics, probiotics and nutritional therapy

Highlights opinion hotspots where treatment approaches differ between physicians and also between the US and Europe, such as the emerging treatment objective of complete mucosal healing

Assesses the impact of the SONIC trial

- Crohn's disease: future treatment scenarios and opportunities

Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.

HIGHLIGHTS

Identifies the latest treatment trends in Crohn's disease, including the growing importance of "top-down" treatment strategies for moderate-to-severe Crohn's disease

Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines

Identifies commercial opportunities in Crohn's disease treatment including:

1. Targeting patients naïve to anti-TNF therapies with novel oral inhibitors

2. Combination therapies with helminth in mild-to-moderate disease

3. Improved localized release of corticosteroids to reduce systemic side effects

Assesses future scenarios for Crohn's disease therapies, including:

1. Migration of anti-TNF therapies to new treatment settings

2. Impact of tailored induction and maintenance regimens

3. Future use of antibiotics, probiotics and helminth in mild-to-moderate disease

To order this report:

Pathology Industry:

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, 2016 ... has entered into a multi-product marketing agreement with ... seven (7) injectable products. Under the terms of ... products under its label in the ... approved ANDA,s and one tentatively-approved ANDA. The products ...
(Date:12/5/2016)... and PUNE, India , December 5, ... by Allied Market Research, titled, "Global Cancer Biomarkers Market - ... of cancer biomarkers market is projected to reach $15,737 million ... of 13.3% from 2016 to 2022. Omic technologies segment accounted ... and is expected to maintain its dominance during the forecast ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology:
(Date:12/5/2016)... , ... December 05, 2016 ... ... interoperability, today announced that the company will provide alerting technology to Central ... been recently awarded $1.7 million in federal funds as the sole sub-recipient ...
(Date:12/5/2016)... ... , ... U.S. Apple Association (USApple) begins the holiday giving season by donating ... for Education: Buy an Apple, Help a Student fundraising campaign. , ... home to their families; solar technology to efficiently process compost; and iPads to enhance ...
(Date:12/5/2016)... ... , ... “Life Will Never Be The Same” is a fictional tale about ... Be The Same” is the creation of published author, Kim T. Briggs, a self-described ... degree in Christian religion and philosophy from Judson University in Elgin, Illinois. Having written ...
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression sleeves come ... buy neoprene knee sleeves for lifting and any sport that requires knee ... two main aspects to provide a higher quality knee sleeve performance. Firstly it is ...
(Date:12/5/2016)... ... December 05, 2016 , ... Z-Medica, LLC, a leading developer ... The American College of Surgeons (ACS) to provide basic bleeding control instructor training ... Basic” course is a pilot program that fulfills the intent of the White ...
Breaking Medicine News(10 mins):